Updated NETs Clinical Trials

1. Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

   Conditions: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) Interventions: Drug: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Drug: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Drug: Amino acid solution; Drug: Lanreotide (Autogel formulation) or Octreotide LAR Sponsors: Grupo Espanol de Tumores Neuroendocrinos; Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) Not yet recruiting

2. Trauma and Cardiometabolic Health in an American Indian Community

   Conditions: Psychological Stress; Cardiometabolic Conditions; Mental Health Interventions: Behavioral: Acute psychological stress task (Paced Auditory Serial Addition Task) Sponsors: Montana State University; National Heart, Lung, and Blood Institute (NHLBI); Baylor University; Blackfeet Community College Recruiting

3. Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

   Conditions: Intestinal Neuroendocrine Tumor Interventions: Other: Additional blood tests (CRP and serum albumin) and data collection. Sponsors: Institut Claudius Regaud Recruiting

4. Insomnia´s Impact on DNA Stability, Cardio-metabolic Health and Lifestyle Behaviors

   Conditions: Insomnia; Cardiorespiratory Fitness; Metabolic Disease Interventions: Other: Exercise; Other: Bioelectrical Impedance; Genetic: Micronucleus Assay; Behavioral: Physical activity and sedentary time; Behavioral: Sleep; Biological: blood sampling; Behavioral: psychometrics; Behavioral: Nutritional Supplement; Genetic: Genotyping Sponsors: Universidad Autonoma de Baja California; Universidad de Granada; University of Colorado, Denver; Instituto Nacional de Salud Publica, Mexico Recruiting

5. National Study of Adrenal Tumours

   Conditions: Pheochromocytoma and Paraganglioma (PPGL); Adrenocorticol Cancer (ACC); Adrenal Tumours Sponsors: Society for Endocrinology Enrolling by invitation

6. Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma

   Conditions: Pancreatic Steatosis; Pancreatic Cyst; Pancreatic Adenocarcinoma Interventions: Diagnostic Test: computerized tomography; Diagnostic Test: Endosonography (EUS) Sponsors: Carol Davila University of Medicine and Pharmacy Recruiting

7. Adjuvant Chemotherapy for High Malignant Prostate Cancer

   Conditions: Prostate Cancer; Radiation Therapy; Chemotherapy; Gleason Score Interventions: Drug: Docetaxel Sponsors: Peking University First Hospital Recruiting

8. The Impact of Selected Probiotic Bacteria on Gut Microbiota, Stress Indicators and Nutritional Status of Young Adults

   Conditions: Healthy Volunteers; Young Adult; Women Interventions: Dietary Supplement: Intervention (Sanprobi®Stress); Other: Placebo Sponsors: Poznan University of Life Sciences Completed

9. A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

   Conditions: Neuroendocrine Tumors, NET Sponsors: First Affiliated Hospital, Sun Yat-Sen University Completed

10. Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

    Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Neoplasm Interventions: Drug: Somatostatin analog Sponsors: The Netherlands Cancer Institute; Neuroendocrine Tumor Research Foundation Recruiting

11. Stress Ball Effects to Pain, Anxiety, Satisfaction and Treatment Continuity During ESWL

    Conditions: Urolithiasis; Extracorporeal Shock Wave Lithotripsy Interventions: Other: Stress ball Sponsors: Mersin University Not yet recruiting

12. Quality of Life and Decisional Regret in Patients Affected by Acoustic Neuroma

    Conditions: Quality of Life Outcomes; Acoustic Schwannoma Sponsors: IRCCS Azienda Ospedaliero-Universitaria di Bologna Recruiting

13. Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects with Advanced Solid Tumors Expressing Somatostatin Receptors

    Conditions: Advanced Solid Tumors Interventions: Drug: MB0151 for injection Sponsors: Mainline Biosciences (Shanghai) Co., Ltd Not yet recruiting

14. Association Between Preoperative Anxiety and Blood Eosinophil Levels

    Conditions: Preoperative Anxiety; Preoperative Evaluation; STAI; Eosinophil Blood Count Sponsors: Naime Yalçın Enrolling by invitation

15. High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins

    Conditions: Breast Carcinoma; Prostate Cancer Surgery; Thyroid Cancer; Parathyroid Adenomas; Skin Cancer; Genitourinary Cancer; Head and Neck Cancer; Hepatobiliary Cancers; Metabolic Abnormality; Neuro Endocrine Tumours; Brain Tumours; Gastro Intestinal Cancer; Thoracoscopic Surgery Interventions: Other: Single intravenous injection of the radiotracer; Diagnostic Test: Imaging resected specimen using the high-resolution PET-CT specimen imager Sponsors: Algemeen Ziekenhuis Maria Middelares Recruiting

16. A Randomised Controlled Trial on the Networks Integrating Anxiety and Metabolism in Anorexia Nervosa

    Conditions: Anorexia Nervosa Interventions: Dietary Supplement: Meal with 400 kilocalories; Dietary Supplement: Meal without calories Sponsors: Umeå University; Ege University Medical School Recruiting

17. Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

    Conditions: DLL3-expressing Tumors; Advanced Tumors Interventions: Drug: Tarlatamab treatment Sponsors: Jonsson Comprehensive Cancer Center; Amgen Not yet recruiting

18. Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )

    Conditions: Pancreatic Adenocarcinoma Interventions: Device: Therapeutic procedure combines EUS-Guided Radiofrequency Ablation (RFA) Sponsors: French Society of Digestive Endoscopy Not yet recruiting

19. Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

    Conditions: Small-Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Carcinoma of the Lung Interventions: Drug: 225Ac-ABD147 Sponsors: Abdera Therapeutics Inc. Recruiting

20. Acute Effects of Ultra-processed Versus Unprocessed Foods on Glucocorticoid Secretion in Healthy Individuals

    Conditions: Glucocorticoids; Obesity and Overweight; Food Effect Interventions: Other: Ultra-processed breakfast; Other: Low-processed breakfast Sponsors: Eleonora Seelig Recruiting

21. Somatic Psychoeducational Intervention

    Conditions: Work Related Stress Interventions: Behavioral: Somatic Psychoeducational Intervention Sponsors: University of Florida Completed

22. Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

    Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Refractory Solid Tumor; Cancer; Lung Cancer; Triple Negative Breast Cancer; Breast Neoplasms; Neuroendocrine Tumors; Neuroendocrine Carcinoma Interventions: Drug: CID-078 Monotherapy Sponsors: Circle Pharma Recruiting

23. Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

    Conditions: Vestibular Schwannoma Interventions: Combination Product: AAVAnc80-antiVEGF via Akouos Delivery Device Sponsors: Akouos, Inc.; Eli Lilly and Company Recruiting

24. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

    Conditions: Pancreatic Ductal Adenocarcinoma; Cholangiocarcinoma; Gastric Cancer; Bladder Cancer; Hepatocellular Carcinoma; Pheochromocytoma; Ovarian Cancer Interventions: Drug: [18F]FAPI-74; Drug: [18F]FDG Sponsors: National Cancer Institute (NCI) Recruiting

25. NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

    Conditions: Non-squamous Metastatic Non-Small-Cell Lung Carcinoma Sponsors: AstraZeneca Recruiting

26. [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

    Conditions: Head and Neck Tumors; Kidney Cancers; Small Cell Lung Cancers; Pheochromocytoma/Paragangliomas; Gastrointestinal Neuroendocrine Tumors; Somatostatin Receptor Positive Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Not yet recruiting

27. Semi-automatic Segmentation Method for Determining 177Lu-DOTATATE Tumor Dosimetry

    Conditions: Meningioma Interventions: Device: scintigraphy of 177Lu-DOTATATE Sponsors: Central Hospital, Nancy, France Completed

28. 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)

    Conditions: Neuroendocrine Tumors Interventions: Drug: 61Cu-NODAGA-LM3; Other: Comparator Sponsors: University Hospital, Basel, Switzerland Recruiting

29. Androgen Effects on the Reproductive Neuroendocrine Axis

    Conditions: Transgenderism; Reproductive Issues Interventions: Drug: Testosterone Cypionate 50 MG/ML Injectable Solution Sponsors: University of California, San Diego; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Recruiting

30. Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors Interventions: Diagnostic Test: positron emission tomography (PET) scans Sponsors: Memorial Sloan Kettering Cancer Center; NeuroEndocrine Tumor Research Foundation (NETRF) Recruiting

31. Study of the Value of HPG80 (circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients with an MEN1 Mutation

    Conditions: Neuroendocrine Tumors; MEN1 Mutation Interventions: Biological: blood sample Sponsors: Centre Hospitalier Universitaire Dijon Recruiting

32. Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

    Conditions: Somatostatin Receptor Positive; Gastrointestinal Neuroendocrine Tumors; Pheochromocytoma; Paragangliomas Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Recruiting

33. A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

    Conditions: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine; Neuroendocrine; Carcinoma; Small Cell; Receptors Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Etoposide Sponsors: National Cancer Institute (NCI) Recruiting

34. NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

    Conditions: Metastatic Neuroendocrine Prostate Cancer Interventions: Drug: [68Ga]Ga-PSMA-11; Drug: [68Ga]GA-DOTA-TATE; Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-PSMA-617; Drug: [177Lu]Lu-DOTA-TATE; Drug: [177Lu]Lu-NeoB; Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,; Drug: Gonadotropin-releasing hormone (GnRH) analogues; Drug: GnRH antagonists; Drug: Antiemetics & antinauseants; Drug: Metoclopramide Sponsors: Novartis Pharmaceuticals Recruiting

35. Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

    Conditions: Neuroendocrine Tumors Interventions: Drug: Cessation of somatostatin analogues; Drug: Continuation of somatostatin analogues Sponsors: Australasian Gastro-Intestinal Trials Group; Canadian Cancer Trials Group Recruiting

36. Exploring Methods for Treating Hypergastrinemia in Patients With Autoimmune Gastritis

    Conditions: Autoimmune Gastritis Interventions: Other: oral administration of receives only oral administration of placebo; Other: oral administration of compound digestive enzyme capsule; Other: oral administration of Betaine hydrochloride Sponsors: Jianning Yao Recruiting

37. The Efficacy of Thoracoabdominal Nerve Block With Serratus Intercostal Plane and Rectus Sheath Block in Cholecystectomy

    Conditions: Pain Management Interventions: Procedure: Group M-TAPA; Procedure: Group Serratus Intercostal Plane Block and Rectus Sheath Block Sponsors: Hitit University Completed

38. Clinical Application of the J-PET Scanner Prototype

    Conditions: Prostate Cancer; Prostatic Hyperplasia; Prostatic Neoplasms; Prostate Cancer Metastatic; Neuroendocrine Tumors; Neuroendocrine Carcinoma Interventions: Diagnostic Test: J-PET scan Sponsors: Jagiellonian University; University Hospital in Krakow Recruiting

39. A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

    Conditions: Neuroendocrine Neoplasms Interventions: Drug: [68Ga]Ga-DOTA-TATE; Drug: 68Ge/68Ga Generator Sponsors: Novartis Pharmaceuticals; Eckert & Ziegler Radiopharma GmbH Completed

40. Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

    Conditions: Metastatic Chondrosarcoma; Locally Advanced Chondrosarcoma; Metastatic Sinonasal Adenocarcinoma; Locally Advanced Sinonasal Adenocarcinoma; Metastatic Large-cell Neuroendocrine Carcinoma; Locally Advanced Large-cell Neuroendocrine Carcinoma; Metastatic Olfactory Neuroblastoma; Locally Advanced Olfactory Neuroblastoma; Metastatic Sinonasal Undifferentiated Carcinoma; Locally Advanced Sinonasal Undifferentiated Carcinoma Interventions: Drug: Enasidenib Sponsors: National Cancer Institute (NCI) Recruiting

41. Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

    Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Recruiting

42. DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

    Conditions: Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin Sponsors: Boehringer Ingelheim Recruiting

43. Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors; Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Device: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT); Device: Photon Emission Tomography / CT (PET/CT); Drug: 64Cu-Dotatate; Drug: 177Lu-Dotatate Sponsors: University of Wisconsin, Madison Recruiting

44. Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

    Conditions: Neuroendocrine Carcinomas; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Carcinoma, Adrenocortical; Carcinoma, Adrenal Cortical Interventions: Drug: ADCT-701 Sponsors: National Cancer Institute (NCI) Recruiting

45. A Study of CRD3874-SI in People With Solid Tumors

    Conditions: Sarcoma; Merkel Cell Carcinoma Interventions: Drug: CRD3874 Sponsors: Memorial Sloan Kettering Cancer Center; Curadev Pharma Recruiting

46. Multicenter Trial of ESK981 in Patients With Select Solid Tumors

    Conditions: Pancreatic Adenocarcinoma; Adenosquamous Carcinoma; Pancreatic Neuroendocrine Tumor; Pancreatic Neuroendocrine Carcinoma; Gastrointestinal Neuroendocrine Tumor; Gastrointestinal Neuroendocrine Carcinoma; Neuroendocrine Prostate Carcinoma Interventions: Drug: ESK981 Sponsors: University of Michigan Rogel Cancer Center Recruiting

47. Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study

    Conditions: Pancreatic Neoplasm Interventions: Procedure: Chemical Ablation; Procedure: Computed Tomography; Other: Electronic Health Record Review; Procedure: Endoscopic Ultrasound-Guided Fine-Needle Aspiration; Procedure: Endoscopic Ultrasound-Guided Radiofrequency Ablation; Procedure: Magnetic Resonance Cholangiopancreatography; Procedure: Magnetic Resonance Imaging Sponsors: Ohio State University Comprehensive Cancer Center Recruiting

48. Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

    Conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma; Unresectable Merkel Cell Carcinoma Interventions: Drug: Avelumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Tuvusertib Sponsors: National Cancer Institute (NCI) Recruiting

49. The Neuroendocrine Effects of Pioglitazone in Patients with Cancer and Cachexia

    Conditions: Lung Cancer Interventions: Drug: Pioglitazone 45 mg; Drug: Placebo Sponsors: Pennington Biomedical Research Center Active, not recruiting

50. The Efficacy of Mapping for Cognitive Prostate Biopsy

    Conditions: Prostate Cancer; Prostate Adenocarcinoma; Prostatic Neoplasms; Prostate Disease; Prostate Cancer Stage Interventions: Procedure: Performing cognitive prostate biopsy with a radiologist's guidance with map; Procedure: Performing cognitive prostate biopsy without a radiologist's guidance with map Sponsors: Marmara University Completed